William Gottschalk

Dermatology, Oncology, Neurology, Cardiology

Role: Area Manager at Castle Biosciences, Inc.
Location: Macon, GA, US
LinkedIn followers: 500 followers

OperationsView LinkedIn profile

About William Gottschalk

Sales Executive Seventeen Years of Sales experience. Exceptional performance in Medical…

Experience

Area Manager
Castle Biosciences, Inc.
Mar 2022 — Present · Macon, GA, US
Aggressive promotion and education on prognostic and diagnostic Gene Expression Profile portfolio targeting Cutaneous Melanoma and Squamous Cell Carcinoma. Call points include Dermatology, Mohs Surgeons, Dermatopathologists, Cancer Centers, Medical Oncology, Surgical Oncology, General Surgery, and Radiation Oncology. Territory includes Atlanta South, Augusta, Columbus, Macon, Albany, Valdosta and surrounding.* 2023 Achieved Over 100% in Melanoma and Squamous Cell Categories

Education

Mercer University
Master's degree
Georgia Southern University
Bachelor's degree

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@castlebiosciences.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Castle Biosciences, Inc.

Biotechnology Research · 781 employees · Founded 2008 · Friendswood, Texas, United States

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. The Company’s innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. Castle currently markets five proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, Barrett’s esophagus, and uveal melanoma. DecisionDx®-Melanoma, Castle’s test for invasive cutaneous melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. DecisionDx®-SCC is the Company’s GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. MyPath® Melanoma provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. TissueCypher® Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus. DecisionDx®-UM, the standard of care in uveal melanoma staging, is Castle's GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. Castle Biosciences is based in Friendswood, TX, (a suburb of Houston) and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.

castlebiosciences.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About William Gottschalk

Experience

Area Manager

Education

Mercer University

Georgia Southern University

Find verified contacts for anyone on LinkedIn